SCHEMBL5834819

SCHEMBL5834819

CCN(CC)c1ccc(NC(=O)C2(N(CC(C)(C)C)C(=O)O)CCc3cccc(Cl)c3C2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 7/20 0.43
GFER P55789 6/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KCNH2 Q12809 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 7/20 0.39
MAPK1 P28482 4/20 0.39
ALDH1A1 P00352 4/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALOX15 P16050 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTT P42858 2/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835590 1.00 GHSR (0.43) GHSRGFERMEN1KMT2AKCNH2
SCHEMBL5835444 0.88 GHSR (0.55) GHSRMEN1KMT2AKCNH2SMN1; SMN2
SCHEMBL5836249 0.88 GHSR (0.55) GHSRMEN1KMT2AKCNH2SMN1; SMN2
SCHEMBL5834813 0.78 GHSR (0.63) GHSRGFERMEN1KMT2ASMN1; SMN2
SCHEMBL5835587 0.78 GHSR (0.63) GHSRGFERMEN1KMT2ASMN1; SMN2
SCHEMBL5835630 0.77 GHSR (0.61) GHSRMEN1KMT2AKCNH2SMN1; SMN2
SCHEMBL5836507 0.77 GHSR (0.61) GHSRMEN1KMT2AKCNH2SMN1; SMN2
SCHEMBL5836093 0.69 GHSR (0.58) GHSRGFERMEN1KMT2ASMN1; SMN2
SCHEMBL5835215 0.69 GHSR (0.80) GHSRGFERMEN1KMT2AKCNH2
SCHEMBL5835783 0.69 GHSR (0.54) GHSRGFERMEN1KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115767-B2 Tetraline derivatives as ghrelin receptor modulators ABBOTT LABORATORIES (US) 2006-10-03 US disclosed
US-20050014794-A1 Tetraline derivatives as ghrelin receptor modulators ABBVIE INC. 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014794-A1 Tetraline derivatives as ghrelin receptor modulators GPR119, GHSR, GIPR GHSR 2/4885GFER 3648/4885MEN1 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.